Peter Powchik - Regeneron Pharmaceuticals Senior Vice President - Clinical Development

REGN -- USA Stock  

USD 286.15  9.72  3.29%

Dr. Peter Powchik, M.D., is Senior Vice President Clinical Development of the Company. Dr. Powchik was employed at several pharmaceutical companies, serving as Senior Vice President and Chief Medical Officer of Chugai Pharma USA, a position he held from May 2005 until October 2006. From April 2001 until May 2005, he held various senior clinical development positions at Novartis Pharmaceuticals Corporationrationration, most recently as Vice President, US Clinical Development and Medical Affairs. Dr. Powchik held various clinical development positions with Sepracor Inc. and Pfizer Inc. from October 1996 to April 2001. Dr. Powchik received his M.D. from New York University School of Medicine.
Age: 59  President Since 2006      

Peter Powchik Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Paul SilvaVertex Pharmaceuticals Incorpor
Sripada ChandrasekharDr Reddys Laboratories Ltd
Thomas FarringtonPerrigo Company plc
Stefan WeiskopfZoetis
Ganadhish KamatDr Reddys Laboratories Ltd
Ronald JanishPerrigo Company plc
Michael StewartPerrigo Company plc
Jeffrey NeedhamPerrigo Company plc
Umang VohraDr Reddys Laboratories Ltd
Alok SonigDr Reddys Laboratories Ltd
John HendricksonPerrigo Company plc
Reshma KewalramaniVertex Pharmaceuticals Incorpor
Joyce LeeZoetis
Thomas GraneyVertex Pharmaceuticals Incorpor
Paul WeningerPerrigo Company plc
James DillardPerrigo Company plc
Catherine KnuppZoetis
Louis YuPerrigo Company plc
James MichaudPerrigo Company plc
Grainne QuinnPerrigo Company plc
Andrew FentonZoetis

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Competition Analyzer Now


Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased one share of
few hours ago
Traded for 1221.15
Purchased over 100 shares of
few hours ago
Traded for 19.55
Purchased over 40 shares of
few hours ago
Traded for 43.23
Purchased over 60 shares of
few hours ago
Traded for 30.83
Purchased few shares of
few hours ago
Traded for 111.18
Additionally take a look at Your Equity Center. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.